Table 4 Clinical findings related to ELABELA levels in patients with CLL
From: Can ELABELA be a novel target in the treatment of chronic lymphocytic leukaemia?
Variables | Study population | CLL | ||
|---|---|---|---|---|
ELABELA | ELABELA | |||
r | p | r | p | |
Disease duration | – | – | −0.153 | 0.332 |
Stage | – | – | −0.246 | 0.116 |
Haemoglobin | 0.050 | 0.655 | 0.087 | 0.582 |
WBC | 0.357 | 0.001* | 0.087 | 0.585 |
Neutrophil | 0.091 | 0.411 | 0.051 | 0.748 |
Lymphocyte | 0.362 | 0.001* | 0.068 | 0.667 |
Platelet | −0.202 | 0.067 | −0.041 | 0.797 |